前列腺癌（PCa）是一种在世界范围内患病率和发病率都很高的疾病。筛查追求的是这种疾病的早期诊断，以提供早期治疗。我们试图描述当地医院患者的诊断和分期特征，并将这些结果与之前报告的数据进行比较。我们对一家机构医院诊断为 PCa 的患者进行了回顾性分析。收集诊断时的临床变量、分期方法、TNM 分期和组织学分级。分析中纳入了 129 名患者。诊断时的中位 PSA (ng/mL) 为 7.29。 37.5% 的组织学分级为 ISUP 1。 42.19% 的患者进行了 MRI 检查，主要被分类为 PIRADS 4 (21.09%)。 PET-CT PSMA 分期主要用于高危组，其他组首选对比增强 CT 和骨闪烁扫描。 6.25%为N1，9.37%为M1。我们系列中的诊断分期略高于发达国家报告的分期，但大大低于其他拉美国家甚至我国其他医院公布的分期。制定明确的筛查和 PSA 获取方案以减少晚期诊断病例具有重要的国家意义。

Prostate cancer (PCa) is a disease with a high prevalence and incidence worldwide. Screening has pursued the early diagnosis of this disease to provide early treatment. We sought to characterize patients from a local hospital with respect to diagnosis and staging and to compare these results with previously reported data.We conducted a retrospective analysis of patients diagnosed with PCa at an institutional hospital. Clinical variables were collected at the time of diagnosis, staging methods, TNM stage, and histological grade.129 patients were included in the analysis. The median PSA (ng/mL) at diagnosis was 7.29. The histological grade was classified as ISUP 1 in 37.5%. An MRI was performed in 42.19% of the patients, being classified mostly as PIRADS 4 (21.09%). PET-CT PSMA staging was used mainly in the high-risk group, preferring contrast-enhanced CT and bone scintigraphy in the other groups. 6.25% were classified as N1 and 9.37% as M1.The stage at diagnosis in our series is somewhat higher than that reported by developed countries but considerably lower than that published by other Latin American countries and even from other hospitals in our country. It is of great national relevance to have clear protocols for screening and access to PSA to reduce the cases diagnosed in advanced stages.